Sunflower Therapeutics

What Sunflower Therapeutics does

Sunflower Therapeutics, PBC is a Massachusetts-based biotechnology company founded in 2018 that develops modular, automated, single-use microbial bioprocessing equipment for continuous protein manufacturing. Its core technology is continuous perfusion fermentation using a proprietary in-vessel cell retention device and yeast (Komagataella phaffii / Pichia pastoris) as the expression host, yielding manufacturing processes with ~50% fewer steps, 10X higher yields, 7X smaller facility footprints, and ~90% reductions in energy and water consumption versus conventional batch biomanufacturing. The product platform consists of the benchtop Daisy Petal® Perfusion Bioreactor System (1L working volume), the Dahlia Petal™ scale-up system (15L working volume, 200L+ output in a 1.5 sq meter footprint), and a GMP-compliant software suite — HelianthOS™ for automation, Nursery™ for recipe design, and Harvest™ for data management — designed to 21 CFR Part 11 standards. A CRO services arm offers strain engineering, media optimization, perfusion fermentation, and purification development.

Sunflower serves global biopharmaceutical companies, vaccine manufacturers, academic researchers, biotech startups, alternative protein companies, and global health organizations. Its customers to date include the Serum Institute of India (GMP installation), BioBuilder (workforce training), and BioTesserae (veterinary biologics co-development). The company monetizes through bioprocessing equipment sales, software licensing, and contract research services, with all pricing handled via custom quotes rather than published tiers. Go-to-market is hybrid: direct enterprise sales for flagship accounts combined with an expanding network of exclusive regional distributors covering Japan (MATSUBO), India and Southeast Asia (PharmNXT), Scandinavia (Alflow), and the US West Coast (Optimal Biotech), now spanning 15+ countries.

The company has been funded primarily through non-dilutive grants — including a $10.5M DOD/JPEO-CBRND contract, $17.1M+ from the Bill & Melinda Gates Foundation, and a $2.36M NIH SBIR Phase II award — plus approximately $5M in SAFE equity investments led by SK bioscience. Operating as a Public Benefit Corporation, Sunflower's mission is to expand global access to biologic medicines by simplifying and decentralizing protein manufacturing, with an explicit footprint push into alternative proteins and LMIC vaccine capacity.

Name

Sunflower Therapeutics

Legal name

Sunflower Therapeutics, PBC

Website

https://sunflowertx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Sunflower Therapeutics is a Massachusetts biotech that builds modular, automated single-use microbial bioreactor systems using continuous perfusion fermentation, serving vaccine manufacturers, biopharma companies, academic researchers, and alternative protein producers globally.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing Equipment

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Continuous Bioprocessing Technologies (perfusion, continuous chromatography, integrated lines) (HLAAAJAH)

akta.pro secondary industry

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

Keywords

• Perfusion bioreactor systems
• Biopharmaceutical manufacturing equipment
• Microbial protein production
• Bioprocessing software solutions
• Contract biomanufacturing services

Headquarters

HQ city

Hingham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Bioprocessing Equipment Sales: Sale of Daisy Petal® and Dahlia Petal™ Perfusion Bioreactor Systems, including hardware, single-use consumables, and associated ancillaries. Equipment sales to pharmaceutical companies, vaccine manufacturers, biotech companies, and academic/research institutions.
2. Software Licensing (HelianthOS™, Nursery™, Harvest™): GMP-compliant software suite (HelianthOS™, Nursery™, Harvest™) sold as part of the equipment platform or as standalone licensing. Includes process automation, recipe development, and secure data management.
3. Contract Research Organization (CRO) Services: Contract research services for process development including strain engineering, media optimization, perfusion fermentation, purification development, and process scaling. Services help customers evaluate and optimize manufacturability of protein products.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Sunflower Therapeutics develops and manufactures automated perfusion bioreactor systems — the Daisy Petal® and the larger-scale Dahlia Petal™ — for protein production via yeast-based continuous perfusion fermentation. The systems are paired with a proprietary GMP-compliant bioprocessing software suite (HelianthOS™, Nursery™, Harvest™) and complemented by contract research organization (CRO) services covering protein expression, process development, and continuous biomanufacturing.

Product overview

Sunflower Therapeutics offers a modular, integrated biomanufacturing platform consisting of two perfusion bioreactor systems (Daisy Petal® for benchtop R&D and Dahlia Petal™ for commercial scale-up), a proprietary software suite (HelianthOS™ for automation, Nursery™ for recipe building, and Harvest™ for data management), and contract research organization (CRO) services for strain engineering, media development, fermentation, and purification. The platform is designed for continuous, automated, single-use microbial bioprocessing using yeast hosts, reducing facility size by 7X, increasing yield by 10X, and cutting energy/water use by 90%, with the goal of making protein manufacturing accessible to anyone.

Differentiator

Problem solved

Functional benefit

Products and services

• Daisy Petal® Perfusion Bioreactor System An automated perfusion bioreactor system designed for bench- and pilot-scale protein production using yeast-based continuous perfusion fermentation. Targeted at biopharmaceutical manufacturers, vaccine producers, biotech companies, and academic researchers who need GMP-compatible continuous bioprocessing with a small footprint. The system is operable by non-expert users, supports remote operation, and is designed to be transferable to global health and distributed manufacturing settings.
• Dahlia Petal™ Perfusion Bioreactor System Sunflower's largest microbial perfusion fermentation system, extending the perfusion bioreactor platform to higher-volume production. Targeted at biopharma, vaccine manufacturers, and alternative protein/bioindustrial producers needing larger-scale continuous fermentation with the same low-footprint, accessible operating profile as the Daisy Petal®.
• HelianthOS™ Bioreactor Operating System A GMP-compliant bioreactor operating system that runs the Daisy Petal® and Dahlia Petal™ systems. Provides remote operation, audit trails, and real-time bioprocess control, and is designed to be operable by non-expert users in GMP manufacturing environments.
• Nursery™ Process Planning Software Process planning software that generates ready-to-run protocols and batch records for bioprocess execution. Targeted at bioprocess engineers and manufacturers who need to standardize protocols, accelerate scale-up, and simplify batch documentation across the Sunflower platform.
• Harvest™ Data Management & Analytics Software Data management and analytics software for bioprocess data captured by the Sunflower platform. Provides visualization, historical data access, and operational analytics for users running continuous bioprocesses on the company's bioreactor systems.
• Contract Research Organization (CRO) Services Contract research services covering protein expression, bioprocess development, and continuous biomanufacturing on the Sunflower perfusion platform. Targeted at biopharma, vaccine developers, biotech companies, academic researchers, and global health organizations that need expert execution of microbial protein production projects.

Quantifiable outcome

• 10X increased protein yield compared to conventional batch fermentation
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Seven partnerships are on record, tiered key, flagship and standard.

• MATSUBO CorporationkeyChannel Partner/ Reseller/ Distributor · 11 February 2026MATSUBO Corporation is engaged as the exclusive distributor for the Daisy Petal® Perfusion Bioreactor System in Japan. MATSUBO provides total support including consulting prior to introduction, engineering services for installation and localization, and maintenance. This is Sunflower's second commercial partnership in Asia.
• Serum Institute of India (SIIPL)flagshipStrategic or Co-development Partner · 3 December 2025Major installation of Daisy Petal® systems completed at the Serum Institute of India (world's largest vaccine manufacturer). Systems installed in GMP space to enable perfusion fermentation, enabling faster, higher-yield protein production in a compact, user-friendly platform.
• Alflow Scandinavia A/SkeyChannel Partner/ Reseller/ Distributor · 24 July 2025Alflow Scandinavia A/S is engaged as the exclusive distributor for the Daisy Petal® Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower's first commercial partnership in Europe, representing a key step in its international growth strategy.
• BioBuilderkeyStrategic or Co-development Partner · 19 May 2025BioBuilder received the first system delivery and installation of the Daisy Petal® Perfusion Bioreactor System. The system was installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for training local students, educators, and incumbent workers in the growing biotechnology workforce.
• Optimal Biotech GroupstandardChannel Partner/ Reseller/ Distributor · 12 May 2025Optimal Biotech Group holds an exclusive sales representation agreement covering customers in California, Oregon, Washington, Idaho, Montana, and British Columbia who wish to purchase the Daisy Petal®.
• PharmNXT Biotech LLPkeyChannel Partner/ Reseller/ Distributor · 26 February 2025PharmNXT Biotech LLP is engaged as a distributor for the Daisy Petal® Perfusion Bioreactor System. With this agreement, the Daisy Petal® is commercially launched and available for sale in India, Singapore, Thailand, Indonesia, Malaysia, and South Korea.
• BioTesserae Inc. (BTC)keyStrategic or Co-development Partner · 14 April 2024BioTesserae Inc. collaborated with Sunflower Therapeutics to produce BTC-001, a PD-1 single domain antibody for treating cancer in companion animals. The product was well tolerated in healthy dogs following a single ascending dose study, demonstrating successful collaboration in veterinary biologics manufacturing.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sartorius: Global leader in bioprocessing equipment, bioreactors, and consumables for the biopharmaceutical industry. Directly comparable as a manufacturer of fermentation and cell culture systems, but operates a much broader portfolio across filtration, fluid management, and lab products.
• Cytiva (Danaher): Major bioprocessing platform from Danaher offering bioreactors, chromatography, and process development tools used in vaccine and biologics manufacturing. Comparable as a supplier of fermentation equipment and bioprocess software, but at much greater scale and with established GMP customer relationships.
• Thermo Fisher Scientific: Diversified life sciences tools leader with a substantial bioproduction offering including single-use bioreactors, process development services, and GMP-compliant software. Comparable as a broad incumbent serving biopharma manufacturing customers with overlapping equipment and services.
• Eppendorf: Established manufacturer of laboratory and bioprocessing equipment including bench-scale bioreactors and fermentation systems. Comparable as a supplier of bioreactor hardware, but with a much broader product portfolio across liquid handling, cell handling, and lab consumables.

Direct peers

• Repligen: Specialized bioprocessing company focused on single-use solutions, bioreactors, and process analytics for biopharmaceutical manufacturing. Most directly comparable in scale and focus to Sunflower as a mid-sized bioprocessing pure-play with innovation-led differentiation.
• PBS Biotech: Developer of single-use, high-cell-density bioreactor systems for cell therapy, gene therapy, and biopharmaceutical applications. Comparable as a smaller competitor in single-use bioreactor hardware targeting similar bioprocessing customers seeking cost-efficient, scalable production.
• Applikon Biotechnology (Getinge): Specialty bioreactor manufacturer (part of Getinge) offering stainless-steel and single-use bioreactor systems for bioprocess development and production. Comparable as a dedicated bioreactor vendor targeting both R&D and GMP manufacturing customers.

Emerging players

• Culture Biosciences: Cloud-based bioprocess development platform offering fermentation services and remote bioreactor access for biotech R&D. Comparable in providing accessible bioprocessing infrastructure to researchers and small biotechs, with a digital-first model similar in spirit to Sunflower's 'Plug-N-Produce' positioning.
• Bota Bio: Synthetic biology and biomanufacturing company combining strain engineering, fermentation, and process development for sustainable production of high-value molecules. Comparable as a younger peer using microbial hosts and integrated bioprocessing to serve alternative protein, cosmetic, and pharmaceutical customers.
• Univercells: Belgian-scaleX™ biomanufacturing company focused on decentralized, low-footprint production of vaccines and biologics for emerging markets. Comparable in mission and product philosophy — small-footprint, automated, distributed biomanufacturing — with overlapping customers in global health and LMIC vaccine producers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sunflower Therapeutics